drugset / Trial / NCT01127178
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of poly (ADP-Ribose) polymerase inhibitor E7016 when used with temozolomide (TMZ) in patients with advanced solid tumors and gliomas.
Timeline
- Start
- 2010-03-29
- Primary completion
- 2011-02-24
- Completion
- 2011-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | E7016 | Small molecule | — | Oral |
| Background | Temozolomide | Small molecule | — | Oral |